- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06654752
Tratamento simplificado de exacerbações pulmonares em pediatria (STOP PEDS RCT)
Tratamento simplificado de exacerbações pulmonares em ensaio clínico randomizado e controlado em pediatria (STOP PEDS RCT)
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Visão geral do estudo
Status
Condições
Descrição detalhada
The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.
Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.
The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.
Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:
- Clinic throat swab substudy
- Home throat and nasal swab substudy
- Remote monitoring substudy (Home monitoring of lung function, vital signs, activity and sleep)
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Erika Enright
- Número de telefone: 206-897-1922
- E-mail: eenright@uw.edu
Locais de estudo
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6H 3V4
- Recrutamento
- British Columbia Children's Hospital
-
Investigador principal:
- Jonathan Rayment, MD
-
Contato:
- Ronak S Ravandi
- E-mail: ronak.salamatravandi@bcchr.ca
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 0A4
- Recrutamento
- The Hospital for Sick Children & Toronto Canada CF Centre Pediatrics
-
Investigador principal:
- Felix Ratjen, MD
-
Contato:
- Claire Crompton
- E-mail: claire.crompton@sickkids.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Recrutamento
- The Children's Hospital Alabama & University of Alabama at Birmingham
-
Investigador principal:
- Christopher Fowler, MD
-
Contato:
- Valerie Tarn
- Número de telefone: 2056385134
- E-mail: vtarn@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85713
- Recrutamento
- Tucson Cystic Fibrosis Center
-
Investigador principal:
- Cori Daines, MD
-
Contato:
- Elizabeth (Lisa) Ryan
- E-mail: elizabethryan@arizona.edu
-
-
California
-
Los Angeles, California, Estados Unidos, 90027
- Recrutamento
- Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic
-
Investigador principal:
- Martha McKinney, MD
-
Contato:
- Ariana Teame, BA
- E-mail: ateame@chla.usc.edu
-
Palo Alto, California, Estados Unidos, 94304
- Recrutamento
- Stanford University
-
Contato:
- Tina Conti, BSRC, RRT, RRT-NPS, C-NPT
- E-mail: tconti@stanford.edu
-
Investigador principal:
- Lori WaiHang Lee, MD
-
San Diego, California, Estados Unidos, 92123
- Ainda não está recrutando
- Rady Children's Hospital at University of California San Diego
-
Contato:
- Lisa Ramos, CRC
- E-mail: lramosvallejo@health.ucsd.edu
-
Investigador principal:
- Kathryn Akong, MD
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- Children's Hospital of Colorado
-
Investigador principal:
- Jordana Hoppe, MD
-
Contato:
- Mary Cross
- E-mail: Mary.Cross@childrenscolorado.org
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Children's Healthcare of Atlanta & Emory University
-
Contato:
- Joy Dangerfield
- E-mail: jdanger@emory.edu
-
Investigador principal:
- Ajay Kasi, MD
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Recrutamento
- Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University
-
Investigador principal:
- Maria Dowell, MD
-
Contato:
- Lisa Gallo, CRC
- Número de telefone: 312-227-2473
- E-mail: lgallo@luriechildrens.org
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Recrutamento
- Riley Hospital for Children & Indiana University
-
Contato:
- Lisa Bendy
- E-mail: lbendy@iu.edu
-
Investigador principal:
- D. B. Sanders, MD, MS
-
Contato:
- Misty Thompson
- E-mail: misthomp@iu.edu
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa
-
Contato:
- Mary Teresi
- E-mail: mary-teresi@uiowa.edu
-
Investigador principal:
- Anthony Fischer, MD
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Recrutamento
- Johns Hopkins Hospital, Johns Hopkins University
-
Contato:
- Jamelia Maynard
- E-mail: jmaynar8@jhmi.edu
-
Investigador principal:
- Peter Mogayzel, MD, PhD, MBA
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Recrutamento
- Boston Children's Hospital & Harvard University
-
Contato:
- Monica Ulles
- E-mail: monica.ulles@childrens.harvard.edu
-
Investigador principal:
- Gregory Sawicki, MD
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109-5212
- Recrutamento
- University of Michigan Health System
-
Contato:
- Dawn Kruse
- E-mail: dmkruse@med.umich.edu
-
Investigador principal:
- Samya Nasr, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55404
- Recrutamento
- Children's Hospitals and Clinics of Minnesota
-
Investigador principal:
- Brooke Moore, MD
-
Contato:
- Danniella Balangoy
- E-mail: Danniella.Balangoy@childrensmn.org
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Recrutamento
- The Minnesota Cystic Fibrosis Center & University of Minnesota
-
Investigador principal:
- Samuel Goldfarb, MD
-
Contato:
- Alyssa Perry
- E-mail: ahperry@umn.edu
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Recrutamento
- Children's Mercy Hospital
-
Contato:
- Jana Lomonte
- E-mail: jblomonte@cmh.edu
-
Investigador principal:
- Hugo Escobar, MD
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- St. Louis Children's Hospital & Washington University School of Medicine
-
Investigador principal:
- Jessica Pittman, MD
-
Contato:
- Taylor Haas, RN, BSN
- E-mail: koenigt@wustl.edu
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- Recrutamento
- University of Rochester Medical Center Strong Memorial
-
Contato:
- Barbara Johnson, RN
- E-mail: Barbara_johnson@urmc.rochester.edu
-
Investigador principal:
- Matthew McGraw, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Recrutamento
- University of North Carolina at Chapel Hill
-
Investigador principal:
- Jennifer Goralski, MD
-
Contato:
- Caroline Flowers, CRC
- E-mail: caroline_flowers@med.unc.edu
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Recrutamento
- Cincinnati Children's Hospital Medical Center
-
Investigador principal:
- Gary McPhail, MD
-
Contato:
- Sharon Donnelly, RN, BSN, CPN
- E-mail: sharon.kadon@cchmc.org
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239-3098
- Recrutamento
- Oregon Health & Science University
-
Contato:
- Pierce Nusbaum
- E-mail: nusbaum@ohsu.edu
-
Investigador principal:
- Kelvin MacDonald, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- Children's Hospital of Philadelphia & University of Pennsylvania
-
Investigador principal:
- Clement Ren, MD, MBA
-
Contato:
- Matthew Gari
- E-mail: garim@chop.edu
-
Contato:
- Erin Donnelly
- E-mail: donnellye4@chop.edu
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Recrutamento
- Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center
-
Investigador principal:
- Daniel Weiner, MD
-
Contato:
- Tyler Johnston, RN
- E-mail: ateame@chla.usc.edu
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Recrutamento
- Medical University of South Carolina
-
Investigador principal:
- Sylvia E Szentpeter, MD
-
Contato:
- Anushka Phadke, CRC
- Número de telefone: 843-792-4656
- E-mail: phadke@musc.edu
-
Contato:
- Sarah Shine, CRC
- Número de telefone: 843-792-1221
- E-mail: shinesa@musc.edu
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Recrutamento
- University of Texas Southwestern & Children's Health
-
Investigador principal:
- Preeti Sharma, MD
-
Contato:
- Lindsay Allen, CRC
- E-mail: Lindsay.Allen@utsouthwestern.edu
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Texas Children's Hospital & Baylor College of Medicine
-
Investigador principal:
- Fadel Ruiz, MD
-
Contato:
- Mayel Yepez
- E-mail: Mayel.YepezDonado@bcm.edu
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05401
- Recrutamento
- Vermont Children's Hospital & University of Vermont Medical Center
-
Investigador principal:
- Thomas Lahiri, MD
-
Contato:
- Zachary Dichard
- E-mail: Zachary.Dichard@uvmhealth.org
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23298
- Recrutamento
- Virginia Commonwealth University
-
Contato:
- Aleksander Subotic, CRC
- E-mail: aleksandar.subotic@vcuhealth.org
-
Investigador principal:
- Michael T. Schechter, MD
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Recrutamento
- Seattle Children's Hospital
-
Investigador principal:
- Margaret Rosenfeld, MD
-
Contato:
- Marissa Nelson, CRC
- Número de telefone: 206-987-3921
- E-mail: marissa.nelsen@seattlechildrens.org
-
Contato:
- Elizabeth Gore, RN, MPH
- Número de telefone: 206-987-3317
- E-mail: Liz.Gore@seattlechildrens.org
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Recrutamento
- University of Wisconsin
-
Investigador principal:
- Hara Levy, MD
-
Contato:
- Nikki Cole, BS, RRT, CCRC
- E-mail: ndondlinger@wisc.edu
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Children's Wisconsin & Medical College of Wisconsin
-
Investigador principal:
- Nicholas Antos, MD
-
Contato:
- Laura Robertson, CCRC
- E-mail: lrobertson@mcw.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Age
- For main cohort and non-HEMT cohort: age 6 to <19 years
- For preschool cohort: age 3 to <6 years
-
Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- sweat chloride ≥ 60 mEq/liter
- two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
-
Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study
-
Highly Effective Modulator Therapy
- For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment
- For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
-
For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry
-
For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations
-
Ability to receive text messages and access the internet
Exclusion Criteria:
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
- Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
- Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
- History of solid organ transplant
- History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
- Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
- Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
- Treatment with chronic oral antibiotics other than azithromycin at enrollment
- Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Immediate Antibiotics
Increased airway clearance plus early initiation of oral antibiotics |
Increase airway clearance and start 14 days of preselected oral antibiotics right away |
|
Experimental: Tailored Therapy
Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve |
Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
One-year change in pulmonary function by spirometry-measured ppFEV1
Prazo: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease. |
1 year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
One-Year change in pulmonary function by LCI
Prazo: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity [FRC]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level. |
1 year
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Recovery to baseline by ppFEV1 and CRISS following a PEx
Prazo: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Recovery to baseline by Lung Clearance Index (LCI)
Prazo: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Safety Endpoint 1: Cumulative oral antibiotic exposure
Prazo: 1 year
|
Compare cumulative oral antibiotic exposure in each treatment arm. |
1 year
|
|
Safety Endpoint 2: Number of respiratory illnesses
Prazo: 1 year
|
Compare the number of respiratory illnesses reported over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx
Prazo: 28 days
|
Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm. |
28 days
|
|
Safety Endpoint 4: Number of PEx treated with IV antibiotics
Prazo: 1 year
|
Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28
Prazo: 28 days
|
Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm. |
28 days
|
|
Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28
Prazo: 1 year
|
Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm. |
1 year
|
|
Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness
Prazo: 1 year
|
Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm. |
1 year
|
|
Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)
Prazo: 1 year
|
Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm. |
1 year
|
|
Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures
Prazo: 1 year
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm. |
1 year
|
|
Qualitative Assessment 1: Caregivers' experience managing study treatment
Prazo: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Qualitative Assessment 2: Study treatment impact on child and family daily life
Prazo: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Health care costs 1: Total estimated cost of antibiotics
Prazo: 1 year
|
Compare total estimated cost of antibiotics used over the course of the study between treatment arms. |
1 year
|
|
Health care costs 2: Health care utilization
Prazo: 1 year
|
Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits. |
1 year
|
|
Health care costs 3: Parent work productivity measures (WPAI)
Prazo: 1 year
|
To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment. |
1 year
|
|
Preschool and non-HEMT Pilot Cohort Primary Feasibility
Prazo: 28 days
|
Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx). |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery
Prazo: 28 days
|
Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery
Prazo: 28 days
|
Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events
Prazo: 28 days
|
Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms
Prazo: 28 days
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics
Prazo: 28 days
|
Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx
Prazo: 28 days
|
Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1
Prazo: 28 days
|
Measure the proportion of approached patients that enrolls. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2
Prazo: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3
Prazo: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4
Prazo: 28 days
|
Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm. |
28 days
|
|
Clinic Throat Swab Substudy 1: Metagenomic Sequencing
Prazo: 1 year
|
Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms. |
1 year
|
|
Clinic Throat Swab Substudy 2: Microbiota Measures
Prazo: 1 year
|
Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments. |
1 year
|
|
Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency
Prazo: 28 days
|
Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis. |
28 days
|
|
Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing
Prazo: 28 days
|
Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx). |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery
Prazo: 28 days
|
Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1
Prazo: 28 days
|
Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.
Prazo: 28 days
|
Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment. |
28 days
|
|
Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes
Prazo: 28 days
|
Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy. |
28 days
|
|
Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx
Prazo: 28 days
|
Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study. |
28 days
|
|
Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx
Prazo: 14 days
|
Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study. |
14 days
|
|
Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry
Prazo: 28 days
|
Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28). |
28 days
|
|
Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures
Prazo: 28 days
|
Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state. |
28 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx
Prazo: 14 days
|
Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx
Prazo: 14 days
|
Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx
Prazo: 14 days
|
Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx
Prazo: 14 days
|
Describe changes in sleep time from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages
Prazo: 14 days
|
Compare changes in resting HR to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages
Prazo: 14 days
|
Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages
Prazo: 14 days
|
Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages
Prazo: 14 days
|
Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)
Prazo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate
Prazo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level
Prazo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration
Prazo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Margaret Rosenfeld, MD, MPH, Seattle Children's Hospital
- Investigador principal: D. B. Sanders, MD, MS, Indiana University
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- STOP PEDS RCT
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .